IL-33 antibody (N-Term)
-
- Target See all IL-33 (IL33) Antibodies
- IL-33 (IL33) (Interleukin 33 (IL33))
-
Binding Specificity
- N-Term
-
Reactivity
- Human
-
Host
- Rabbit
-
Clonality
- Polyclonal
-
Conjugate
- This IL-33 antibody is un-conjugated
-
Application
- Western Blotting (WB)
- Specificity
- IL33 antibody was raised against the N terminal of IL33
- Purification
- Affinity purified
- Immunogen
- IL33 antibody was raised using the N terminal of IL33 corresponding to a region with amino acids AKEVCPMYFMKLRSGLMIKKEACYFRRETTKRPSLKTGRKHKRHLVLAAC
- Top Product
- Discover our top product IL33 Primary Antibody
-
-
- Application Notes
-
WB: 1 µg/mL
Optimal conditions should be determined by the investigator. - Comment
-
IL33 Blocking Peptide, catalog no. 33R-1291, is also available for use as a blocking control in assays to test for specificity of this IL33 antibody
- Restrictions
- For Research Use only
-
- Format
- Lyophilized
- Reconstitution
- Lyophilized powder. Add distilled water for a 1 mg/mL concentration of IL33 antibody in PBS
- Concentration
- Lot specific
- Buffer
- PBS
- Handling Advice
-
Avoid repeated freeze/thaw cycles.
Dilute only prior to immediate use. - Storage
- 4 °C/-20 °C
- Storage Comment
- Store at 2-8 °C for short periods. For longer periods of storage, store at -20 °C.
-
- Target
- IL-33 (IL33) (Interleukin 33 (IL33))
- Alternative Name
- IL33 (IL33 Products)
- Synonyms
- IL33 antibody, C9orf26 antibody, DVS27 antibody, IL1F11 antibody, NF-HEV antibody, NFEHEV antibody, RP11-575C20.2 antibody, 9230117N10Rik antibody, Il-33 antibody, Il1f11 antibody, RGD1311155 antibody, interleukin 33 antibody, IL33 antibody, Il33 antibody
- Background
- Cytokine that binds to and signals through IL1RL1/ST2 and its stimulation recruits MYD88, IRAK1, IRAK4, and TRAF6, followed by phosphorylation of MAPK3/ERK1 and/or MAPK1/ERK2, MAPK14, and MAPK8. IL33 induces T helper type 2-associated cytokines.
- Molecular Weight
- 31 kDa (MW of target protein)
- Pathways
- Production of Molecular Mediator of Immune Response
-